New Therapeutic Strategies for Gliomas: From the Bench to the Bedside
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 April 2019) | Viewed by 452
Special Issue Editors
Interests: gliomas; precision medicine; patient-based in vitro models of glioma; exosomes; stem cells; tumor microenvironment
Interests: neurosurgery; glioma; meningioma; glioblastoma; brain mapping; real-time neuropsychological testing; brain tractography
Special Issues, Collections and Topics in MDPI journals
Interests: neuro-oncology; glioblastoma; gliomas; targeted therapy; brain tumors; immunotherapy; quality of life
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Glioblastoma (GBM) is the most frequent malignant primary tumor of the central nervous system characterized by an extremely severe prognosis. Despite a multimodal therapy involving maximal surgical resection, followed by radiotherapy, plus concomitant and maintenance temozolomide, the median overall survival of GBM patients is around 14 months. The urgent need of identifying new therapies has fostered wide genome analyses that, so far, have identified the GBM IDH1/2 mutant as characterized by a better prognosis. Meanwhile, MGMT promoter methylation is endowed with a predictive significance. Nonetheless, basic, translational, and clinical research is working hard to try to improve the prognosis of this deadly disease.
In this issue, starting from the definition of the current gold standard for the treatment of glioblastoma, we will explore novel therapeutic interventions focusing on different levels of investigations:
- Technical advancement in gold standard procedures, such as those aimed at improving surgical radicality and radiotherapy (including brachytherapy, fractionated stereotactic RT, radiosurgery, and conformal or intensity-modulated RT, stereotactic radiosurgery, hypofractionated stereotactic radiotherapy);
- Introduction in clinics of proton-therapy, immunotherapy, Tumor-Treating Electric Fields, and targeted therapies;
- Radiomics and liquid biopsy as a way to tailor patient treatment;
- Looking for new therapeutic targets, including glioma stem cells, glioma microenvironment, extracellular vesicles, cell invasion, glioma metabolism;
- Looking for new drugs, including in silico and in vitro drug screening;
- Looking for new models of study, including patient-based in vitro models, organoids, and novel animal models of glioblastoma.
The final aim of the review is to give an overview of the rich and complex world of research focused on the treatment of glioblastomas, from close to the introduction in the clinic to what, even though far from the patient’s bed, could be able to modify the prognosis of this terrible disease in the future.
Dr. Daniela Cesselli
Dr. Tamara IUS
Dr. Giuseppe Lombardi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Glioblastoma therapy
- Targeted therapy
- Radiotherapy and proton-therapy
- Tumor-Treating Electric Fields
- Phototherapy
- Immunotherapy
- Precision and personalized medicine
- Drug screening: In silico and in vitro approaches
- Novel in vitro model to predict drug sensitivity
- Predict drug response: Radiomics and liquid biopsy
- treatment of low and high grade glioma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
